Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Immune-related adverse events
•
Neurology
•
Neuromuscular
How do you manage immunotherapy-induced myasthenia gravis?
Answer from: at Academic Institution
My go-to algorithm is well-represented in the paper by Dr. @Adeel Zubair et al. Zubair et al., PMID 36439604
Sign In
or
Register
to read more
Answer from: Medical Oncologist at Community Practice
NCCN "Management of Immunotherapy-Related Toxicities" has a useful 'cheat sheet' as a quick reference for the overnight call.
Sign In
or
Register
to read more
19074
19390
Related Questions
What treatments, after appropriate dose reductions/delays, do you offer for patients with oxaliplatin-induced cold allodynia/dysesthesia?
Do you consider immunosuppression in patients with a history of Sjogren's disease and clinical features of inclusion body myositis?
When would you consider testing for LGI1 antibodies in patients with unexplained neuropathic pain?
What is your approach to patients with diffuse, patchy paresthesias affecting the head, face, lips, and/or tongue?
How do you approach weaning treatments for CIDP in remission?
How do you counsel patients and doctors on antibiotic avoidance in myasthenia gravis?
How do you use serum IgG levels when treating with FcRN inhibitors?
How do you counsel patients who wish to travel to high altitudes with myasthenia gravis?
When do you use rozanolixizumab for Musk MG?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?